Evidence map›Paper›PMID 40575414›Full record

ArticleNeuro-oncology advances

Molecular alterations in

Keng Lam, Hanim I Ozkizilkaya, Denái R Milton, Antonio Dono, Yajie Liu, Suprateek Kundu, Vinodh A Kumar, Jason M Johnson, Yoshua Esquenazi, Chirag B Patel and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MedComm · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Keng LamDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-4480-2801
Hanim I OzkizilkayaDepartment of Pathology, University of Southern California.
Denái R MiltonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA.
Antonio DonoDepartment of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8041-8399
Yajie LiuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA.
Suprateek KunduDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA.
Vinodh A KumarDepartment of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, USA.
Jason M JohnsonRadiology and Biomedical Imaging, Yale University, New Haven, USA.
Yoshua EsquenaziDepartment of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9757-1453
Chirag B PatelDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-0787-0634
Leomar Y BallesterDivision of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6854-6830

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Development and Validation of a CSF Liquid Biopsy for Molecular Characterization and Monitoring of Patients with Central Nervous System TumorsK08CA241651 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BALLESTER, LEOMAR Y · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA241651NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Background: Several molecular alterations have been identified to provide prognosis for patients with isocitrate dehydrogenase (IDH)-mutant astrocytoma. However, contemporary baseline survival data with respect to their molecular alterations are lacking. The prognostic value of histologic grading remains controversial. Methods: This was a retrospective multi-site study of adult IDH-mutant diffuse astrocytoma patients. Overall survival (OS) was estimated using the Kaplan-Meier method. Associations between OS and measures of interest were evaluated using Cox proportional hazards regression models. Results: We identified 241 eligible patients. The most frequent mutations were IDH1 (98%), TP53 (91%), ATRX (70%), ARID1A (8%), BRCA2 (6%), TSC2 (6%), CDKN2A (6%), and CREBBP (6%). IDH2 mutations were identified in 2%. By univariate analysis, age > 40 (hazard ratio [HR], 2.03; 95% CI, 1.20-3.45; Conclusions: Age and CNS WHO grade remain essentials for risk stratification among

Indexed as

astrocytomabrain tumordiffuse gliomaIDH1IDH2molecular alterationsprognosisWHO grade

Identifiers

PMID40575414
PMCPMC12199353

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.